MLTX has faded since a mid-June rally on year-long hidradenitis suppurativa data and an August psoriatic arthritis readout, ...
Interim data from the 393-patient phase 3 CERVINO trial of etentamig (ABBV-383), a bispecific CD3 and BCMA-directed TCE, ...
The expanded interchangeability now applies to the 40mg prefilled syringe and the 40mg and 80mg autoinjectors, in addition to the 20mg and 80mg prefilled syringes. The Food and Drug Administration ...
Samsung Bioepis and Organon shared that the Food and Drug Administration has designated the Hadlima (adalimumab-bwwd) high- and low-concentration (40 mg/0.4 ml, 40 mg/0.8 ml) autoinjectors and ...
The Food and Drug Administration (FDA) has designated Hadlima™ (adalimumab-bwwd) an interchangeable biosimilar to Humira ® (adalimumab). With this approval, pharmacies can substitute Hadlima for the ...
The Food and Drug Administration has granted an expanded interchangeable designation for Celltrion’s Yuflyma (adalimumab-aaty), now including prefilled syringe (40mg) and autoinjectors (40mg and 80mg) ...
The designation allows pharmacists to substitute it for Humira without prescriber approval (per state law), which expands patient access in the process. Full interchangeability approved: The FDA has ...
Expanded designation now includes 40mg and 80mg autoinjectors and syringes, backed by Phase III data and aligned with Celltrion’s pricing strategy to improve access and affordability in the U.S.
Medicare Part D may cover Humira when a person can self-administer it at home. A person's Part D costs for Humira will depend on the plan's formulary and their specific plan. Similarly, Medicare ...
Credit: Celltrion. Yuflyma, a tumor necrosis factor blocker, was approved in May 2023 as a biosimilar to Humira. Similar PK, efficacy, safety, and immunogenicity data were observed between the ...
The interchangeability designation for Yuflyma, a biosimilar to Humira, may help to improve patient access and reduce costs. The FDA has granted interchangeability designation to Celltrion’s Yuflyma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results